These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 24280068)

  • 21. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).
    Nagar B; Bornmann WG; Pellicena P; Schindler T; Veach DR; Miller WT; Clarkson B; Kuriyan J
    Cancer Res; 2002 Aug; 62(15):4236-43. PubMed ID: 12154025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cross-resistance of imatinib mesylate and 17-AAG in imatinib-resistant cells that overexpress BCR-ABL.
    Topaly J; Schad M; Laufs S; Melo JV; Zeller WJ; Fruehauf S
    Br J Haematol; 2003 May; 121(4):672-3. PubMed ID: 12752112
    [No Abstract]   [Full Text] [Related]  

  • 23. Molecular imaging of Bcr-Abl phosphokinase in a xenograft model.
    Wu JY; Yang DJ; Angelo LS; Kohanim S; Kurzrock R
    Mol Cancer Ther; 2009 Mar; 8(3):703-10. PubMed ID: 19258427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overcoming kinase resistance in chronic myeloid leukemia.
    Lee F; Fandi A; Voi M
    Int J Biochem Cell Biol; 2008; 40(3):334-43. PubMed ID: 18401881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia.
    O'Dwyer ME; Druker BJ
    Lancet Oncol; 2000 Dec; 1():207-11. PubMed ID: 11905636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.
    Wu J; Meng F; Kong LY; Peng Z; Ying Y; Bornmann WG; Darnay BG; Lamothe B; Sun H; Talpaz M; Donato NJ
    J Natl Cancer Inst; 2008 Jul; 100(13):926-39. PubMed ID: 18577747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
    Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
    Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.
    Wu J; Meng F; Lu H; Kong L; Bornmann W; Peng Z; Talpaz M; Donato NJ
    Blood; 2008 Apr; 111(7):3821-9. PubMed ID: 18235045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacology of imatinib (STI571).
    Buchdunger E; O'Reilly T; Wood J
    Eur J Cancer; 2002 Sep; 38 Suppl 5():S28-36. PubMed ID: 12528770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells.
    Greene LM; Kelly L; Onnis V; Campiani G; Lawler M; Williams DC; Zisterer DM
    J Pharmacol Exp Ther; 2007 Apr; 321(1):288-97. PubMed ID: 17202400
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.
    Fernández A; Sanguino A; Peng Z; Ozturk E; Chen J; Crespo A; Wulf S; Shavrin A; Qin C; Ma J; Trent J; Lin Y; Han HD; Mangala LS; Bankson JA; Gelovani J; Samarel A; Bornmann W; Sood AK; Lopez-Berestein G
    J Clin Invest; 2007 Dec; 117(12):4044-54. PubMed ID: 18060038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.
    Al-Ali HK; Heinrich MC; Lange T; Krahl R; Mueller M; Müller C; Niederwieser D; Druker BJ; Deininger MW
    Hematol J; 2004; 5(1):55-60. PubMed ID: 14745431
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice.
    Chen CI; Koschmieder S; Kerstiens L; Schemionek M; Altvater B; Pscherer S; Gerss J; Maecker HT; Berdel WE; Juergens H; Lee PP; Rossig C
    Leukemia; 2012 Mar; 26(3):465-74. PubMed ID: 21904381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Preclinical and clinical profile of imatinib mesilate, a potent protein-tyrosine kinase inhibitor for CML therapy].
    Toga W; Kondo M; Tokoro A
    Nihon Yakurigaku Zasshi; 2003 Feb; 121(2):119-28. PubMed ID: 12616857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.
    Corbin AS; O'Hare T; Gu Z; Kraft IL; Eiring AM; Khorashad JS; Pomicter AD; Zhang TY; Eide CA; Manley PW; Cortes JE; Druker BJ; Deininger MW
    Cancer Res; 2013 Sep; 73(18):5775-86. PubMed ID: 23887971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.
    Gumireddy K; Baker SJ; Cosenza SC; John P; Kang AD; Robell KA; Reddy MV; Reddy EP
    Proc Natl Acad Sci U S A; 2005 Feb; 102(6):1992-7. PubMed ID: 15677719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.
    Okabe S; Tauchi T; Nakajima A; Sashida G; Gotoh A; Broxmeyer HE; Ohyashiki JH; Ohyashiki K
    Stem Cells Dev; 2007 Jun; 16(3):503-14. PubMed ID: 17610380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
    Lee J; Shen P; Zhang G; Wu X; Zhang X
    Biomed Pharmacother; 2013 Mar; 67(2):157-63. PubMed ID: 23201011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
    Ebos JM; Tran J; Master Z; Dumont D; Melo JV; Buchdunger E; Kerbel RS
    Mol Cancer Res; 2002 Dec; 1(2):89-95. PubMed ID: 12496355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.
    Wu LX; Wu Y; Chen RJ; Liu Y; Huang LS; Lou LG; Zheng ZH; Chen YZ; Xu JH
    Acta Pharmacol Sin; 2014 Mar; 35(3):401-9. PubMed ID: 24487968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.